ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy
At the European Society of Cardiology (ESC) Congress 2024, the cardiology community received its deepest insights yet into the potential of aficamten in the management of hypertrophic cardiomyopathy ahead of the anticipated Q3 submission to the US Food and Drug Administration, including an integrated safety analysis leveraging data from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials.
The study cohort included 170 patients with aficamten and 153 patients treated with placebo from the REDWOOD-HCM and SEQUIOA-HCM trials for the placebo-controlled pool. When including the FOREST-HCM cohort, investigators obtained data from 283 patients, including 100 who transitioned from placebo to aficamten.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
